Long-Term Outcomes of Transarterial Embolization for Pulmonary Arteriovenous Malformations in Pediatric Hereditary Hemorrhagic Telangiectasia
- 28 December 2025
- journal article
- research article
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 49 (2) , 396-408
Abstract
Purpose To assess long-term clinical and radiological outcomes of transarterial embolization (TAE) for pulmonary arteriovenous malformations (PAVMs) in children with hereditary hemorrhagic telangiectasia (HHT). Materials and Methods This retrospective single-center study included 29 pediatric HHT patients (62% male; mean age: 8 [SD: 3]) who underwent TAE for 63 PAVMs in 32 different events between 2004 and 2024. Clinical outcome was peripheral oxygen saturation (SpO2), measured at 1 month, 1, 3, and 5 years. Radiological outcomes included occlusion at final follow-up, persistence, incomplete treatment, reperfusion, and recanalization rates. Regression models were used to identify predictors of SpO2 response and radiological outcomes. Adverse events (AEs) were reported using the CIRSE classification. Results Median SpO2 significantly improved from 95% (IQR: 88–97) to 98% (IQR: 95–99) (p < 0.001), 98% (p < 0.001), 98% (p = 0.002), and 97% (p = 0.03) at 1 month, 1, 3 and 5 years. Diffuse disease (p = 0.024, 0.033) and HHT type 1 (p = 0.023) were associated with lower follow-up SpO2. Occlusion rate at final follow-up was 82.5% with persistence, incomplete treatment, reperfusion, and recanalization rates at 28.6%, 7.9%, 19.0% and 6.3%. Size (p = 0.021), diffuse lesion (p = 0.002), and draining vein number (p = 0.002) predicted persistence; diffuse lesion (p = 0.015) and feeding artery number (p = 0.030) predicted reperfusion; feeding artery number (p = 0.046) predicted recanalization; and size (p = 0.004), diffuse lesion (p < 0.001), feeding artery (p = 0.004), and draining vein number (p = 0.001) predicted incomplete occlusion at final follow-up. AE rate was 12.9%, with most events graded as minor. Conclusion TAE was effective and safe in pediatric HHT patients with PAVMs, achieving durable occlusion and oxygenation improvement. Graphical AbstractKeywords
This publication has 30 references indexed in Scilit:
- CIRSE Standards of Practice for the Classification of Complications: The Modified CIRSE Classification SystemCardioVascular and Interventional Radiology, 2025
- Persistence After Treatment of Pulmonary Arteriovenous Malformations in ChildrenCardioVascular and Interventional Radiology, 2023
- Longitudinal Assessment of Curaçao Criteria in Children with Hereditary Hemorrhagic TelangiectasiaThe Journal of Pediatrics, 2023
- Screening children for pulmonary arteriovenous malformations: Evaluation of 18 years of experiencePediatric Pulmonology, 2017
- Amplatzer Vascular Plugs Versus Coils for Embolization of Pulmonary Arteriovenous Malformations in Patients with Hereditary Hemorrhagic TelangiectasiaCardioVascular and Interventional Radiology, 2016
- Prevalence of Pulmonary Arteriovenous Malformations in Children versus Adults with Hereditary Hemorrhagic TelangiectasiaThe Journal of Pediatrics, 2013
- Long-Term Follow-Up of Treatment of Pulmonary Arteriovenous Malformations with AMPLATZER Vascular Plug and AMPLATZER Vascular Plug II DevicesJournal of Vascular and Interventional Radiology, 2011
- Embolization of Pulmonary Arteriovenous Malformations with Amplatzer Vascular Plugs: Safety and Midterm EffectivenessJournal of Vascular and Interventional Radiology, 2010
- Pulmonary arteriovenous malformations in children: Outcomes of transcatheter embolotherapyThe Journal of Pediatrics, 2004
- Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)American Journal of Medical Genetics, 2000